Key result
Black race is linked to ~29% lower odds of BP control in patients on ≥3 antihypertensives.
Why the study?
Failure to control blood pressure despite multiple prescribed antihypertensive medications is widespread and recent changes to US BP targets require updated evaluation including medication adherence and therapeutic inertia.
Cohort (n=565,737)
Yes
Odds Ratio: 0.71 (95% CI 0.7–0.73)
In a large US cohort of patients on ≥3 antihypertensives, blood pressure control remains poor, driven by both high rates of medication nonadherence and widespread therapeutic inertia.
Disparities in BP control among patients on multiple antihypertensives merit attention; leaves open whether addressing racial and insurance barriers improves outcomes.
BACKGROUND: Failure to control blood pressure (BP) despite multiple prescribed antihypertensive medications (AHMs) is widespread and leads to worse clinical outcomes. Recent changes to BP targets in US clinical guidelines require an updated evaluation of BP control including evaluations of nonadherence and therapeutic inertia. METHODS: We leveraged clinical and insurance data sourced from >50 US health care organizations to identify >500 000 patients with established hypertension (>15-month history) concurrently prescribed ≥3 AHM classes in 2019. We characterized the prevalence of uncontrolled hypertension and describe patterns of nonadherence (lack of AHM fills covering >80% of days) and therapeutic inertia (failure to escalate AHM for patients persistently out of BP control). We described the associations with factors including race, ethnicity, sex, and insurance. RESULTS: Among 565 737 patients prescribed ≥3 AHMs, 37.7% met the recommended BP target of <130/80 mm Hg. Black race (odds ratio [OR], 0.71 [95% CI, 0.70-0.73]) and uninsured status (OR, 0.81 [95% CI, 0.76-0.86]) were most associated with lack of BP control relative to White or commercially insured patients. In a subset of insured patients, nonadherence occurred in 52.7%, although BP control remained poor among adherent patients (43.0% versus 39.4% for nonadherent). Therapeutic inertia was widespread; 64.5% of patients persistently above the BP target had no medication escalation within 18 months. CONCLUSIONS: An evaluation of a US-based, large, real-world patient cohort demonstrates that most patients prescribed ≥3 AHMs fail to achieve the recommended BP target of <130/80, and both medication nonadherence and therapeutic inertia are widespread.
No takes yet. Share an insight, caveat, or question.
Mohl et al. (2025) conducted a cohort in Hypertension (n=565,737). Black race vs. White race was evaluated on Blood pressure control (<130/80 mm Hg) (OR 0.71, 95% CI 0.70-0.73). Among US patients prescribed ≥3 antihypertensives, only 37.7% achieved BP control, with Black race associated with lower odds of control compared to White patients (OR 0.71; 95% CI 0.70-0.73).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: